A surprising discovery could change the treatment landscape for medulloblastoma, the most common malignant brain tumor in children. Researchers at Fox Chase Cancer Center have found that triiodothyronine (T3), a cheap, FDA-approved thyroid hormone used for decades to treat hypothyroidism, can forcefully mature tumor cells into a harmless state where they stop dividing. When combined with standard chemotherapy, T3 not only shrank tumors more effectively in laboratory models but also prevented the aggressive relapses that doom up to 30 percent of young patients. The work, published in Molecular Therapy Oncology, opens a fast-track route to a multicenter pediatric clinical trial already underway.
Medulloblastoma arises in the cerebellum and is treated with a punishing triad of surgery, high-dose chemotherapy, and radiation that can leave survivors with lifelong cognitive and physical impairments. Yet even after this assault, tumor regrowth remains a leading cause of death. Zeng‑jie Yang, a professor at Fox Chase’s Cancer Epigenetics Institute, and his team decided to tackle the problem from a fundamentally different angle. Instead of trying to poison every last cancer cell, they asked whether the cells could simply be coaxed to grow up.
The approach is called differentiation therapy, a strategy that has transformed certain blood cancers but has rarely succeeded in solid tumors. Differentiation is the biological process by which immature progenitor cells acquire specialized functions and, crucially, lose the capacity for uncontrolled proliferation. In medulloblastoma, the cancer cells resemble stalled neuronal precursors that never receive the signal to mature. Yang’s group screened for molecules capable of delivering that signal and identified T3, the active form of thyroid hormone, as a potent driver of differentiation in multiple medulloblastoma subtypes.
Thyroid hormone receptors are nuclear transcription factors that, upon binding T3, regulate large sets of genes involved in cell cycle exit and neuronal maturation. The researchers showed that when they exposed medulloblastoma cells to T3 at clinically relevant concentrations, the cells extended neurite-like processes, expressed mature neuronal markers, and permanently exited the cell cycle. Unlike chemo-killed cells that can leave behind resistant clones, differentiated tumor cells are genetically stable and essentially retired from malignant behavior. However, differentiation alone works slowly, so the team combined T3 with standard chemotherapy to attack the tumor on two fronts: cytoreduction by killing cycling cells, and long-term control by maturing the survivors.
In mouse models engrafted with patient-derived medulloblastoma, the combination of chemotherapy followed by T3 suppressed tumor growth far more robustly than chemotherapy alone. Strikingly, tumors treated with chemotherapy alone universally grew back after treatment stopped, whereas those that received post-chemotherapy T3 showed markedly delayed relapse and, in many cases, no regrowth at all. The combination also allowed researchers to drop chemotherapy doses to less toxic levels while maintaining efficacy, and it remained effective against cells that had acquired resistance to standard agents. These results suggest a one-two punch: chemotherapy debulks the mass, and T3 converts the residual cells into a non-threatening state, closing the therapeutic window that normally allows recurrence.
Safety was a paramount concern because the patients are children whose developing brains are exquisitely sensitive to hormonal perturbations. High doses of T3 can temporarily raise heart rate by overstimulating cardiac thyroid hormone receptors. The team addressed this by co-administering the beta-blocker propranolol, a widely used drug that easily controlled heart rate without diminishing T3’s anti-tumor effect or adding toxicity. Yang noted that this simple pharmacological combination makes the potential therapy manageable in a pediatric oncology ward using existing medications.
Because T3 is already FDA-approved, inexpensive, and backed by decades of clinical experience, the path from bench to bedside could be remarkably short. The Pediatric Neuro‑Oncology Consortium, a national network of children’s hospitals, has already launched a multicenter clinical trial to evaluate whether adding T3 to standard treatment safely improves outcomes for children with medulloblastoma. The trial will assess tumor response, relapse rates, and cardiac safety with or without propranolol. If successful, the regimen could be deployed broadly without the decade-long development timelines and prohibitive costs typical of novel cancer drugs.
Yang’s team is also exploring whether differentiation therapy with T3 might apply to other pediatric brain tumors that share similar developmental arrest mechanisms. The concept of pushing cancer cells toward terminal maturation rather than simply killing them could reduce the collateral damage that makes current protocols so devastating for young survivors. For now, the hope is that a humble thyroid hormone, repurposed with surgical precision, might finally break the cycle of relapse that has haunted families facing medulloblastoma.
Subject of Research: Differentiation-inducing triiodothyronine enhances chemotherapy and suppresses post-treatment tumor regrowth in medulloblastoma
Article Title: Differentiation-inducing triiodothyronine enhances chemotherapy and suppresses post-treatment tumor regrowth in medulloblastoma
News Publication Date: 18-Jun-2026
Web References: http://dx.doi.org/10.1016/j.omton.2026.201235
References: 10.1016/j.omton.2026.201235
Image Credits: Yang et al
